Novartis Strikes Kymriah Outcome-Based Deal With German Insurers
Executive Summary
Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.
You may also be interested in...
Italy Unveils New Payment Model For Novartis’s CAR-T Kymriah
The Italian authorities have agreed a new kind of reimbursement model for Novartis's CAR-T therapy Kymriah that involves payment in instalments depending on the patient’s response to treatment.
New Thinking Needed On Reimbursement Of Cell And Gene Therapies
One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.